drugset / Trial / NCT02709993
Consolidation Therapy in Patients With Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of Tumor Associated Peptide Antigen (TAPA) pulsed dendritic cell (DC) vaccines in the treatment of hematologic malignancies.
Timeline
- Start
- 2017-07-28
- Primary completion
- 2020-10-31
- Completion
- 2020-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAPA-pulsed DC vaccine | Cell therapy | 1e+07 cells | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | 100 mg | Oral |
| Background | sargramostim | Protein / enzyme biologic | 50 ug | Subcutaneous |